The rise in profits was attributed to the robust performance in international markets and growth in new launches from ...

Emcure's Poviztra weight loss brand thrives post-price cut, contributing to $1 billion revenue milestone for FY26.

While the broader market remained positive, Emcure Pharma's stock moved in the opposite direction.

The company had posted a consolidated net profit of ₹197.24 crore in the corresponding quarter last fiscal, Emcure ...

Reported Standalone quarterly numbers for Emcure Pharmaceuticals are: Net Sales at Rs 1,467.70 crore in March 2026 up 14.83% ...

The new dosage variant is designed to provide a more effective and convenient option for patients with iron deficiency and iron deficiency anaemia (IDA). DCGI-approved FCM is indicated for the ...

Emcure Pharmaceuticals reported a 23.6% rise in Q4 net profit to Rs 244 crore, with revenue growing 16.7% to Rs 2,470 crore, ...

Emcure Pharma posts 29% profit growth and 17% revenue rise in Q4FY26; stock falls over 5% after hitting a 52-week high of ...

Emcure currently has six biosimilars in the market, launched through its subsidiary Gennova Biopharmaceuticals. While it has ...

Emcure Pharmaceuticals IPO subscription status: The initial public offering of Emcure Pharmaceuticals Ltd kickstarts for subscriptions today (Wednesday, July 3 ...

Namita Thapar simply loves her business. As Executive Director of the India business at Pune-based Emcure Pharmaceuticals, she barely pauses when you ask her what the vision for the company is. “We ...

Emcure Pharmaceuticals Ltd on Tuesday reported a 24 per cent increase in consolidated net profit at ₹243.74 crore in the ...